Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling — Stella

Home/Recurrent Childhood Acute Myeloid Leukemia/Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

View on ClinicalTrials.gov

Recruiting

Back to Recurrent Childhood Acute Myeloid Leukemia trials

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Nicklaus Children's Hospital, Miami, Florida

Key details

Phase

Early testing

Sponsor

Florida International University

Collaborators

Nicklaus Children's Hospital f/k/a Miami Children's Hospital, First Ascent Biomedical Inc.

Enrollment target

~65 participants

Started

February 2023

Primary completion

February 2028

Age range

1 Day – 21 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.